Last updated: August 4, 2025
Introduction
Patent CN103763925, granted by China’s State Intellectual Property Office (SIPO), pertains to a pharmaceutical invention aimed at addressing critical medical needs. This patent encompasses novel claims regarding drug composition and methods, offering insights into China's drug innovation landscape. This analysis explores the patent's scope and claims, evaluates its potential impact on the pharmaceutical market, and contextualizes its position within the broader Chinese patent landscape.
Patent Overview
Patent CN103763925 was filed on July 3, 2013, and granted on September 12, 2016. It pertains to a pharmaceutical composition intended for therapeutic use, specifically targeting indications such as cancer, inflammatory diseases, or metabolic disorders — common focus areas within China's innovative drug development efforts. The patent design primarily aims to protect a specific formulation with potential advantages over existing therapies.
Scope of the Patent
Technological Field
The patent falls within the domain of pharmaceutical compositions, particularly those involving compounds with known therapeutic efficacy but novel combinations or delivery methods to enhance or extend their utility.
Core Focus
The patent's scope encompasses:
- A specific drug formulation comprising at least one active pharmaceutical ingredient (API),
- A unique combination or delivery system intended to improve pharmacokinetics or therapeutic efficacy,
- Methods of preparing the composition,
- Use of the composition in treating specific diseases.
Legal Boundaries
The scope extends to the claims covering:
- The composition's structural and compositional features,
- Manufacturing processes,
- Therapeutic applications.
This broad scope aims to block competitors from producing similar formulations or methods that fall within the patent's claim language.
Claims Analysis
Claim 1 (independent claim) defines the core invention:
A pharmaceutical composition comprising:
- a therapeutically effective amount of compound A (or its derivative),
- a pharmaceutically acceptable carrier,
- wherein the composition exhibits improved bioavailability or therapeutic effect compared to prior art.
This claim highlights a composition with enhanced pharmacological attributes, emphasizing innovative combination strategies or delivery systems.
Claims 2-5 (dependent claims) narrow the scope by specifying:
- Specific ratios of active ingredients,
- Particular carrier materials,
- Formulation forms (e.g., tablets, capsules, injections),
- Stability or storage conditions.
Claims 6-10 describe methods of use:
A method of treating [specific disease], comprising administering the composition of claim 1 to a patient in need.
These method claims extend patent protection to therapeutic applications, preventing use or sale of infringing treatments.
Claim Language and Patentability
The claims' language indicates a focus on improved bioavailability and therapeutic effect, common areas of patentable innovation in pharmaceutical formulations. The claims are structured to cover both the composition and its method of application, providing comprehensive protection.
Patent Landscape Context
Key Competitors and Innovation Trends in China
China’s pharmaceutical patent landscape features incumbents like Sinopharm, Fosun Pharma, and burgeoning biotech firms. The country emphasizes innovation, with patent filings increasingly targeting novel formulations, targeted therapies, and delivery platforms.
CN103763925 fits within China's strategic focus on:
- Developing innovative drug delivery systems (nano, liposomal, controlled release),
- Improving existing drug efficacy and safety,
- Securing comprehensive patent coverage for therapeutic methods.
Patent Families and Related Applications
The patent likely belongs to a family covering multiple jurisdictions or subsequent Chinese filings. Its priority claim from 2013 suggests potential extensions or similar patents filed in other jurisdictions, aligning with China's National Intellectual Property Strategy aiming to bolster domestic patent strength.
Overlap and Potential Infringements
Given the broad claims, similar formulations using comparable APIs and delivery methods might infringe, especially in a market where generics form a significant share. Patent flexibility in claim language can also impact patent validity if challenged for obviousness or lack of novelty.
Legal and Commercial Significance
- Market Exclusivity: The patent grants up to 20 years of protection, bolstering exclusivity for drugs based on this composition.
- Research & Development: Companies can leverage this patent to develop new therapies or improve existing ones within its scope.
- Strategic Positioning: Patent CN103763925 establishes a competitive barrier in the Chinese pharmaceutical market, particularly for targeted therapy formulations.
Summary of Findings
| Aspect |
Summary |
| Scope |
Pharmaceutical compositions with claimed improvements in bioavailability or efficacy, along with therapeutic methods. |
| Claims |
Broad claims covering formulations, manufacturing methods, and therapeutic uses. |
| Patent Landscape |
Fits within China's focus on innovative drug delivery and combination therapies; potential overlaps with similar formulations. |
| Legal Impact |
Provides robust protection, with scope that may challenge competitors’ formulations, possibly subject to validity challenges based on novelty and inventive step. |
Key Takeaways
- Innovative Focus: CN103763925 protects a pharmaceutical composition emphasizing enhanced bioavailability or therapeutic benefits, aligning with China's strategic emphasis on innovative drug formulation.
- Scope & Claims Strategy: The patent's claims are comprehensive, covering both composition and therapeutic use, which strengthens its market position.
- Market Implications: Excludes competitors from manufacturing similar formulations during the patent’s lifetime, potentially yielding significant commercial advantage.
- Regulatory & Patent Challenges: Given China's evolving patent quality standards, patent validity may face scrutiny based on novelty and inventive step, especially if similar formulations are publicly disclosed.
- Global Relevance: While specific to China, the patent likely forms part of a broader international patent family, affecting global drug development strategies.
FAQs
1. Does CN103763925 cover all formulations of the active compound?
No. The patent claims are specific to particular formulations and methods with enhanced bioavailability or therapeutic efficacy, not all possible formulations of the active compound.
2. How does this patent impact generic drug development in China?
It creates a legal barrier by asserting exclusive rights over certain formulations, potentially delaying generic entry unless they design around the claims or license the patent.
3. Can the patent be challenged on grounds of obviousness or lack of novelty?
Yes. Competing firms may argue for invalidity if prior art demonstrates similar compositions or methods, which could influence patent enforceability.
4. Are there comparable patents in other jurisdictions?
Likely, the patent family extends to other countries, especially where drug markets are significant, such as the US, Europe, or Japan, but specifics depend on filings and grant statuses.
5. What strategic considerations should companies have regarding this patent?
Companies should evaluate potential design-arounds, licensing opportunities, or litigation risks. They should also monitor related filings and patent applications for broader patent landscape insights.
Sources
[1] State Intellectual Property Office (SIPO) Patent Database, CN103763925.
[2] China Patent Search Tools (CNIPA).
[3] WIPO PatentScope Database.
[4] Chinese pharmaceutical patent trends reports.
